|CRBC and Ningbo Port interested in concession on the Zagreb Deep Sea Terminal|
|19th May 2019|
|RIJEKA - Seven new companies from Europe, the Middle East and the Far East are interested in the new container terminal in Rijeka, director of the Port Authority, Denis Vukorepa, said for Jutarnji List, but their names and references did not reveal.|
From sources close to the Government, Jutarnji list unoficially acknowledges that among the interested Chinese consortium are Ningbo Port and CRBC (China Road and Bridge Corporation), a company that builds the Peljesac Bridge and Port of Singapore.
After analyzing the documents received, which will last for 15 days, all seven (or only some of the applicants, depending on the quality of their references and project vision) will be invited to bid for a 50-year concession. Estimated value of concession (excluding VAT) is HRK 20.5 billion, a diary is quoted. "This is a respectable terminal terminal operator, and we are very pleased because we wanted such a response, but this trend is still very interesting," says Vukorepa.
The first stage of the concession process has been formally concluded on Friday, and the plan is to sign a complex contract for the Zagreb Deep Sea terminal until the end of September.
The tender is being sought by the concessionaire for the execution of works and the provision of services, and his obligation is an investment of about 70-80 million euros to complete the terminal which is now 400 meters long and was built within the project with the World Bank and the EU. During a visit of China's premier in Croatia, it was announced that the concession was of interest to Chinese companies, but Denis Vukorepa did not want to comment on this information, Jutarnji list writes.
The intention of the state is to build the Zagreb Deep Sea terminal in the second phase up to a total length of 680 meters, and if the concessionaire is not interested in it, the concession will be reduced to 30 years.
|31st March 2021|
|WHO: Sinopharm, Sinovac COVID-19 vaccine data show efficacy|